Antonio Passaro: MARIPOSA Study Shows Amivantamab-Lazertinib Survival Benefit in EGFR-Mutant Lung Cancer
Antonio Passaro, Medical oncologist at the European Institute of Oncology in Milan, shared a post on LinkedIn:
“What a time to be in thoracic oncology! Being at ELCC25 in Paris made me realize once again how fast lung cancer treatment is evolving.
This year’s congress marked the new landmark for patients with EGFR-mutant lung cancer, with the groundbreaking MARIPOSA study demonstrating a significant overall survival benefit for the combo of amivantamab plus lazertinib
I had the privilege of participating in a controversy session to discuss whether combination therapies should now be considered the new standard in this specific oncogene-driven setting—balancing efficacy, tolerability, and disease characteristics to offer the best possible care for our patients.
The future of lung cancer treatment is changing before our eyes, and this was also the focus of my second talk, dedicated to emerging therapies—particularly ADCs targeting c-MET
Every milestone brings us closer to transforming patient care, with the mission to increase the 5-year survival rate in EGFR-mutant NSCLC.”
More posts featuring Antonio Passaro and ELCC25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023